NCT01220869

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

An Open-label, Multi-centre Registration Trial, Investigating Efficacy and Safety of Degarelix One-month Dosing Regimen in Taiwanese Patients With Prostate Cancer Requiring Androgen Ablation Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: Male
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

A phase III trial investigating the efficacy and safety of degarelix one-month depot in Taiwanese patients with prostate cancer.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Degarelix	Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).

Timeline

• Start date: 2010-12-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2010-10-14
• Last updated: 2025-04-13
• Results posted: 2013-12-06

Locations

10 sites across 1 country: Taiwan